Identification of an Internalizing Cancer Target for Novel Antibody Drug Conjugate Development by A&G Pharmaceutical and Precision Antibody Researchers

Precision Antibody and A&G Pharmaceutical are pleased to announce the publication, in PLOS One, of the results of their collaborative study about the identification of Prostaglandin F2 receptor negative regulator as a cancer cell surface target and the isolation of internalizing antibody for antibody drug conjugate development.